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Abstract
Nucleoporins (NUPs) are essential components of the nuclear pore complex (NPC).1 Only few 
diseases have been attributed to NPC dysfunction.2-4 Steroid resistant nephrotic syndrome 
(SRNS), a frequent cause of chronic kidney disease, is caused by dysfunction of glomerular 
podocytes.5 Here we identify in 8 families with SRNS mutations of NUP93, its interaction partner 
NUP205, or exportin5 (XPO5) as a hitherto unrecognized monogenic cause of SRNS. NUP93 
mutations caused disrupted NPC assembly. NUP93 knockdown reduced the presence of NUP205 
in the NPC and, reciprocally, a NUP205 mutation abrogated NUP93 interaction. We demonstrate 
that NUP93 and XPO5 interact with the signaling protein SMAD4, and that NUP93 mutations 
abrogated interaction with SMAD4. Significantly, NUP93 mutations interfered with BMP7-
induced SMAD transcriptional reporter activity. We hereby demonstrate that mutations of NUPs 
cause a distinct renal disease, and reveal SMAD signaling as a novel disease mechanism of SRNS, 
opening a potential new avenue for treatment.
Results
Steroid-resistant nephrotic syndrome (SRNS) is a disease of the renal glomerular filter. It 
constitutes the second most frequent cause of end-stage kidney disease (ESKD) in the first 3 
decades of life.6 Its renal histologic correlate is focal segmental glomerulosclerosis (FSGS), 
which invariably causes loss of renal function within a few years of onset requiring dialysis 
treatment or renal transplantation for survival. Over 30 monogenic genes lead to podocyte 
dysfunction if mutated, which revealed these glomerular epithelial cells as the critical site of 
SRNS.5,7 Disease gene identification also implicated multiple signaling pathways in the 
pathogenesis of SRNS.8-10 We recently demonstrated in a large cohort of 1,780 families 
with SRNS that in about 70% of cases a causative gene is unknown.11
To identify additional genes that cause SRNS if mutated we performed homozygosity 
mapping12 and whole exome sequencing13 in 160 families with SRNS. In three families 
(A1671, A1626, and A2241) (Fig. 1, Table 1, Supplementary Figs. 1 and 2) we detected 2 
different homozygous missense mutations of the gene NUP93 (NM_014669.4) 
(p.Gly591Val and p.Tyr629Cys), which encodes the nuclear pore protein 931 (Table 1, Fig. 
1a, d–e). By high-throughput exon sequencing11,14,15 in a worldwide cohort of 1,800 
families with SRNS we detected 3 additional families (A2403, A3256, and A1394) with 
compound heterozygous truncating mutations or highly conserved missense mutations of 
NUP93 (Table 1, Fig. 1d–e, Supplementary Fig. 2). The variants p.Gly591Val and 
p.Tyr629Cys apparently represent European and Turkish founder alleles, respectively (Table 
1). We show that the splice site mutation (c.1537+1G>A) detected in family A1394 (Table 1, 
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Fig. 1d) leads to aberrant splicing with in-frame skipping of exon 13 (Supplementary Fig. 
1B–E). NUP93 function is known to be essential for NPC assembly in S. cerevisiae,16,17 C. 
elegans, and D. rerio.18
Phenotypically, all 7 individuals of 6 families with recessive NUP93 mutations had SRNS 
that manifested early, i.e. between 1 and 6 years of age, and caused ESKD between ages 1 
and 11 years (Table 1). Renal biopsy revealed FSGS or its developmental equivalent diffuse 
mesangial sclerosis (DMS) in the 5 individuals in whom a biopsy was performed (Table 1, 
Fig. 1b–c,g–h and Supplementary Fig. 3A). In addition, there was a renal tubular phenotype 
with proximal tubular dilation with protein casts and interstitial cell infiltrations (Fig. 1c, 
Supplementary Fig. 3B). Electron microscopy revealed partial podocyte foot process 
effacement (Supplementary Fig. 3C). It is known that glomerular developmental defects 
(diffuse mesangial sclerosis, DMS) and glomerular degenerative defects (focal segmental 
glomerular sclerosis, FSGS) can occur on a monogenic basis due to multiple allelism.19 
However, in NUP93 mutations only one family had features of DMS, whereas 4 others had 
FSGS, making a glomerular developmental defect unlikely. One patient showed partial 
response to steroids, and two patients responded partially to CSA. A partial response to 
therapy with alternative agents is a rare but known feature of monogenic forms of nephrotic 
syndrome that is otherwise steroid resistant.20 However no genotype-phenotype correlation 
has been detected so far in these cases.
In addition, by genetic mapping (Fig. 1f) and whole exome sequencing in two siblings of 
family A1733 with early onset SRNS and FSGS we identified a homozygous missense 
mutation of the nucleoporin NUP205 (NM_015135.2) at a highly conserved amino acid 
residue (p.Phe1995Ser) (Fig. 1f, Table 1, Supplementary Fig. 2). Interestingly, NUP205 is a 
direct protein interaction partner of NUP93 within the inner ring of the NPC.17,21 
Furthermore, by genetic mapping (Fig. 1i) and whole exome sequencing we identified a 
homozygous missense mutation of the nuclear export protein exportin5 (XPO5) 
(NM_020750.2) (p.Val552Ile) in individual F1092 with onset of SRNS at 2 years (Fig. 1i, 
Table 1, Supplementary Fig. 2). Remarkably, XPO5 is known to play a role in nuclear export 
in concert with nucleoporins.22-24
Nucleoporins (NUPs) are highly conserved eukaryotic proteins that form nuclear pore 
complexes (NPCs), huge macromolecular assemblies in the nuclear envelope which mediate 
the transport of proteins, RNAs and RNP particles between cytoplasm and the nuclear 
interior (Supplementary Fig. 4).25,17 NUPs function by interacting with transport receptors 
such as exportins and importins that shuttle their cargo through NPCs (Supplementary Fig. 
4). While monogenic mutations in genes encoding NPC components have only been 
described in three other human diseases,2-4 we here implicate three NPC associated proteins 
in the pathogenesis of SRNS. We find, surprisingly, that very specific recessive mutations in 
genes that have a critical cellular function may cause a distinct renal disease phenotype.
To determine whether the two nucleoporins, NUP93 and NUP205, and the exportin XPO5 
are expressed during renal development, we performed immunofluorescence (IF) studies in 
sections of fetal rat kidney. We observed that at the capillary loop stage of renal glomerular 
development NUP93, NUP205, and XPO5 are present in developing podocytes that are 
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positive for the podocyte nuclear marker WT1 (Supplementary Fig. 5). Interestingly, in adult 
rat glomeruli, XPO5 colocalized in podocytes with synaptopodin, a marker of primary and 
secondary podocyte foot processes, in a pattern that has been described for many other 
products of genes that if mutated cause SRNS (Fig. 2d).8,26,27
To elucidate the role of the nucleoporin NUP93 in the pathogenesis of SRNS, we performed 
in-vitro functional assays in human immortalized podocytes. First, we studied podocyte 
migration, a well-established surrogate phenotype that is typically altered upon loss-of-
function of genes that are involved in nephrotic syndrome.8-10 We show that knockdown of 
NUP93 using 2 different shRNAs resulted in an impaired migratory phenotype that was 
rescued by transfection of wildtype mouse Nup93 (Fig. 2e). Knockdown of the nucleoporin 
NUP153 in which we did not find mutations in individuals with SRNS did not affect 
podocyte migration (Supplementary Fig. 6). Furthermore, we found that upon knockdown of 
NUP93 the proliferation rate of human podocytes is strongly reduced (Fig. 2f). To assess 
oxidative stress resistance, we challenged human podocytes with sub-lethal concentrations 
of H2O2 (100 μM, 250 μM, and 500 μM). While H2O2 at these doses did not affect 
scrambled-control cells, it induced apoptotic cell death shown by increased cleavage of 
caspase-3 in NUP93 knockdown cells (Fig. 2g).
To assess whether the NUP93 mutations that we identified in individuals with SRNS 
interfere with nuclear pore complex (NPC) localization, we performed IF microscopy of the 
proteins of Myc tagged NUP93 constructs in human podocytes (Fig. 3a,c). Upon 
overexpression, wild type or some mutant constructs of NUP93 localized to the nuclear 
envelope, whereas constructs representing the truncating mutation p.Lys442Asnfs*14 and 
the splice site mutation p.del ex13, that we detected in individuals with SRNS (A3256 and 
A1394, respectively), failed to properly mark the nuclear envelope (Fig. 3a,c).
To further evaluate interference of mutations with nuclear envelope integrity, we performed a 
depletion-addback assay in Xenopus laevis egg extracts. In this assay formation of nuclear 
envelopes, indicated by a smooth membrane staining with DiIC18 as well as NPC formation 
(indicated by the antibody AB414) around sperm chromatin (Fig. 3b, upper and second 
rows), was faithfully reconstituted.28 Depletion of Nup93 abrogated nuclear envelope and 
pore formation,29,30 which was restored upon re-addition of wildtype protein or most 
mutants found in individuals with SRNS, but not by mutants del ex13, Arg388Trp, or 
Lys442Asnfs*14 (Fig. 3b,d). NUP93 tightly interacts with NUP20531 and, consistently, 
shRNA knockdown of NUP93 in podocytes caused depletion of NUP205 (Fig. 3e). 
Furthermore, we found that GFP tagged NUP205 interacts with endogenous NUP93 upon 
overexpression in HEK293 cells (Fig. 3f). The mutant NUP205 allele identified in family 
A1733 with SRNS, p.Phe1995Ser, abrogated this interaction (Fig. 3f). However, NUP93 
mutations identified in families with SRNS did not abrogate the interaction with NUP205 
(Supplementary Fig. 7).
It was recently shown that drosophila NUP93 and NUP205, apart from their known roles as 
scaffold nucleoporins in NPC assembly, also have cargo import functions and are essential 
for nuclear import of phosphorylated/activated SMADs (Supplementary Fig. 4).32 
Interestingly, loss of function of other nucleoporins does not affect SMAD signaling.32 
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Following these previous findings, we performed further studies to define the role of NUP93 
in SMAD signaling. Using immunofluorescence in human podocytes, we demonstrate that 
upon stimulation with BMP7 NUP93 colocalizes with the nuclear importer importin7 to a 
nuclear rim structure (Fig. 2a). Interestingly, both proteins also showed strong colocalization 
during different stages of renal development (Fig. 2b–c). Because of the described roles of 
NUP93 in SMAD signaling in drosophila, we explored whether NUP93 interacts with 
SMAD.32 We performed coimmunoprecipitation studies in HEK293 cells (Fig. 4). We 
demonstrate that SMAD4 interacts with endogenous NUP93 when overexpressed in 
HEK293 cells, which we confirmed for endogenous SMAD4 (Fig. 4a–b). Furthermore, we 
show that upon BMP7 stimulation NUP93 interacts with the phosphorylated/activated form 
of endogenous SMAD1/5 (Fig. 4d). Interestingly, the 3 NUP93 mutations 
p.Lys442Asnfs*14, p.Gly591Val, and p.Tyr629Cys that we found in patients with SRNS 
(Table 1, Fig. 1d–e) abrogated this interaction (Fig. 4c), likely reflecting their pathogenicity 
(Table 1). The abrogation of interaction was confirmed reciprocally (Supplementary Fig. 8).
Because of the suggested role of the karyopherin importin-7 (Msk) in NUP93 mediated 
nuclear import of SMAD,32,33 we explored whether the NUP93 mutations that we identified 
in individuals with SRNS affect BMP7 dependent SMAD signaling. We found that NUP93 
and SMAD4 both interact with endogenous importin7 in humans (Fig. 4e–f). The same 3 
mutations (p.Lys442Asnfs*14, p.Gly591Val, p.Tyr629Cys) that disrupted interaction with 
SMAD4 (Fig. 4c, Table 1, Fig. 1d–e) also abrogated interaction of NUP93 with importin7 
(Fig. 4g). In addition, we found that NUP93 colocalizes importin7 in different stages of 
glomerular development and in podocyte precursor cells at the early capillary loop stage 
(Fig. 2b–c).
BMP7 plays a crucial role in renal development.34 Furthermore, growing experimental 
evidence suggests that BMP7 is an important mediator of renal response to injury, and has 
protective effects in multiple animal models of acute and chronic renal injury.35 BMP7 
balances the profibrotic effects of TGF-β, and it has been shown that loss of SMAD4 
promotes renal fibrosis and inflammation.36 In addition, BMP7 inhibits apoptotis and 
promotes podocyte survival in experimental models of diabetic nephropathy.37 Since, 
podocytes and collecting duct cells were shown to be the primary target cells of BMP7 in the 
kidney,38 we explored whether the NUP93 mutations that we identified in individuals with 
SRNS affect BMP7 dependent SMAD signaling. We demonstrate that knockdown of NUP93 
in human podocytes using two different shRNAs disrupts BMP7 dependent activation of 
SMAD signaling as demonstrated by reduced nuclear accumulation of SMAD4 after BMP7 
stimulation (Fig. 5a). An equivalent result was seen when using HEK 293 (Supplementary 
Fig. 9). Consistently, expression of mouse wildtype Nup93 but none of the 5 mutants 
detected in individuals with SRNS rescued the BMP7 dependent nuclear translocation of 
endogenous SMAD4 in knockdown cells (Fig. 5b, Supplementary Fig. 9B).
Upon shRNA knockdown of NUP93 in HEK293 cells BMP7 treatment failed to induce 
SMAD dependent reporter activity when compared to scrambled control (Fig. 5c). 
Reciprocally, whereas transfection of wild type full-length mouse Nup93 (under NUP93 
knockdown) restored BMP7 dependent SMAD reporter activity, none of the constructs 
reflecting the 5 mutations detected in individuals with SRNS rescued SMAD4 dependent 
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transcription (Fig. 5c). Furthermore, upon treatment of human podocytes with BMP7, 
importin-7 localizes to a nuclear rim structure in control cells (Fig. 2a, Fig. 5d). Knockdown 
of NUP93 by two different shRNAs inhibited this rim formation (Fig. 5d). Knockdown of 
the nucleoporin NUP188 in which we did not find mutations in individuals with SRNS did 
not reduce SMAD reporter activity in our assay (Supplementary Fig. 10).
We demonstrated loss of function for all NUP93 mutations detected in individuals with 
SRNS. NUP93 mutations either disrupt NPC integrity (Fig. 3a–c) (mutations p.del ex13, 
p.Arg388Trp, and p.Lys442Asnfs*14) or abrogate the interaction of NUP93 with SMAD4 
(Fig. 4c) or importin7 (Fig. 4g) (mutations p.Lys442Asnfs*14, p.Gly591Val, p.Tyr629Cys) 
(see middle column of Table 1). In all individuals with mutations in NUP93 there was a 
defect in SMAD signaling, suggesting SMAD signaling as the relevant pathogenic pathway 
shared by these mutations. Furthermore, we show that XPO5, which we found defective in 
another individual with SRNS (Fig. 1i, Table 1) also interacts with SMAD4 (Fig. 4h).
In summary, we here demonstrate that specific mutations of NUP93, NUP205, or XPO5 
cause a distinct entity of SRNS and we introduce the terms “NPHS11”, “NPHS12”, and 
“NPHS13”, respectively. We thereby link NPC associated proteins to a new pathogenic 
pathway for SRNS. Furthermore, we implicate BMP7 dependent SMAD signaling as a novel 
disease mechanism of SRNS, thereby potentially opening new approaches towards its 
therapy.
Online Methods
Research subjects
We obtained blood samples and pedigrees following informed consent from individuals with 
SRNS. Approval for human subjects research was obtained from Institutional Review 
Boards of the University of Michigan, and Boston Children's Hospital. The diagnosis of 
steroid-resistant nephrotic syndrome was based on published clinical criteria.
Linkage analysis
For genome-wide homozygosity mapping the GeneChip® Human Mapping 250k StyI Array 
from Affymetrix was used. Non-parametric LOD scores were calculated using a modified 
version of the program GENEHUNTER 2.140,41 through stepwise use of a sliding window 
with sets of 110 SNPs and the program ALLEGRO42 in order to identify regions of 
homozygosity as described12,43 using a disease allele frequency of 0.0001 and Caucasian 
marker allele frequencies. For graphical presentation (Fig. 1a, f, i, Suppl. Fig. 1) non-
parametric lod scores (NPL) were calculated and plotted across the human genome. The x-
axis shows Affymetrix 250K StyI array SNP positions on human chromosomes concatenated 
from p-ter (left) to q-ter (right). Genetic distance is given in cM.
Whole exome sequencing
Whole exome sequencing (WES) and variant burden analysis was performed as described 
previously44. In brief, genomic DNA was isolated from blood lymphocytes and subjected to 
exome capture using Agilent SureSelect™ human exome capture arrays (Life 
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technologies™) followed by next generation sequencing on the HiSeq Illumina™ 
sequencing platform as previously described.
Mutation calling
Sequence reads were mapped against the human reference genome (NCBI build 37/hg19) 
using CLC Genomics Workbench (version 6.5.1) software (CLC bio). Variants with minor 
allele frequencies <1% in the dbSNP (Version 137) database were selected and annotated for 
impact on the encoded protein and for conservation of the reference base and amino acid 
among orthologs across phylogeny. Mutation calling was performed by geneticists/cell 
biologists, who had knowledge of the clinical phenotypes and pedigree structure, as well as 
experience with homozygosity mapping and exome evaluation.
High-throughput mutation analysis by array-based multiplex PCR and NGS
We used PCR-based 48.48 Access Array microfluidic technology (Fluidigm™) with 
consecutive next generation sequencing. We applied a 12-fold primer multiplexing approach 
allowing PCR-based amplification for 48 DNA samples simultaneously in 576 
amplicons.14,15 A total of 1,800 individuals with nephrotic syndrome were analyzed, among 
them subset of 500 individuals with proteinuria and hematuria. After amplification of all 
targeted coding and splice site regions, sample-derived products were indexed with 384 
different 10 bp-barcodes in a subsequent PCR. Finally, 2 × 250bp paired-end sequencing 
was performed on an Illumina™ MiSeq instrument. Bioinformatic analysis was conducted 
using CLC-Genomics-Workbench™ software. Potential mutations were confirmed by 
Sanger sequencing and evaluated for segregation. Primer sequences for targeted exon 
sequencing are provided in Suppl. Table 1.
cDNA and splice mutation
RNA of A1394-21 was purified from whole blood (purelink, Invitrogen) and cDNA was 
synthesized using a high fidelity RT-PCR system (Agilent Technologies). RT-PCR was 
performed on cDNA from A1394-21 and from healthy controls using exonic primers 
flanking exon 13. PCR products were Sanger sequenced and analyzed on an agarose gel to 
test for exon skipping (Suppl. Fig. 1).
cDNA cloning
Human NUP93 full-length cDNA was subcloned by PCR from human full-length cDNA 
(cDNA clone MGC: 21106 IMAGE: 4750923). Mouse NUP93 was subcloned from mouse 
NUP93 full-length cDNA (cDNA clone MGC: 28230, IMAGE: 3991335). Human NUP205 
subcloned from human full-length cDNA (cDNA clone MGC: 168237 IMAGE: 9020614). 
Human XPO5 full-length was subcloned from human full-length cDNA (cDNA clone MGC: 
74566 IMAGE: 5492046). Human SMAD4 full-length was subcloned from human full-
length cDNA (cDNA clone MGC: 8602 IMAGE: 2961238), human SMAD2 was subcloned 
from human full-length cDNA (cDNA clone MGC: 34440 IMAGE: 5221801), human 
SMAD5 was subcloned from human full-length cDNA (cDNA clone MGC: 8960 IMAGE:
3906006). Mouse Ipo7 was subcloned from mouse full-length Importin7 (cDNA clone, 
MGC: 175386, IMAGE: 100014508). Expression vectors were produced using LR clonase 
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(Invitrogen®) following the manufacturer's instruction. The following expression vectors 
were used in this publication: pRK5-N-Myc, pCDNA6.2-N-GFP, pCDNA6.2-C-GFP, pCS-
Dest2, and pSirenRetroQ. Clones reflecting the mutations identified in individuals with 
SRNS were introduced in the cDNA constructed using the Quick change II XL site-directed 
mutagenesis kit, Agilent Technologies. This technique was also applied to generate a human 
SMAD4 construct lacking the canonical nuclear export signal (amino acids 142-149).45
Cell lines
Experiments shown in this publication were performed in HEK293T cells and immortalized 
human podocytes. HEK293T cells were purchased from the ATCC biological resource 
center. Human immortalized podocytes were a kind gift from Moin Saleem, University of 
Bristol, Bristol, UK, and were cultured as previously described.46 Cell lines were tested for 
mycoplasma contamination on a quarterly basis.
Coimmunoprecipitation
Coimmunoprecipitation experiments were performed as described previously.47 Briefly, cell 
lysates were pre-cleared with protein G or A beads. Then, cell lysates were mixed with the 
appropriate antibodies and incubated overnight at 4°C in lysis buffer containing the 
complete protease inhibitor mixture. Immune complexes were collected by binding to mixed 
protein G or A beads and washed four times with lysis buffer prior to immunoblotting. 
Coimmunoprecipitation of GFP fusion proteins was performed using Chromotek-GFP-
Trap® Agarose Beads, allele bioscience. Coimmunoprecipitation experiments were 
performed in three independent experiments, and protein-protein interactions were 
confirmed reciprocally.
SMAD translocation assays
Human immortalized podocytes were transfected with scrambled or shRNA against human 
NUP93 (see Suppl. Table 1 for targeted sequences). For rescue experiments, a second 
transfection with pCDNA6.2-N-GFP-MOCK, pCDNA6.2_murine Nup93 wildtype, or 
pCDNA6.2_murine Nup93 mutant clones was performed after 24 hrs. 60 minutes prior to 
the experiment cells were exposed to 100 ng/ml recombinant BMP7 (rc-BMP7, R&D 
systems). The knockdown efficiency, as well as effective activation of the BMP7-SMAD1/5 
pathway was confirmed by immunoblotting (Fig. 3d, Suppl. Fig. 11).
SMAD reporter gene assay
The SMAD reporter assay was performed using the Cignal SMAD Reporter (luciferase) 
assay (Qiagen®) following the manufacturer's protocol. In brief, HEK293 cells were 
transfected with the Cignal SMAD reporter construct and scrambled or shRNA against 
human NUP93. After 24 hours cells were transfected with murine Nup93 (WT or mutants) 
or pCDNA6.2-N-GFP-MOCK. Eighteen hours prior to the experiment, cells were exposed 
to 100 ng/ml recombinant BMP7 (rc-BMP7, R&D systems). Luciferase activities were 
measured using Dual-Luciferase® Reporter Assay and GloMaxTM 96 microplate 
luminometer (Promega) according to the manufacturer's instruction. The luciferase activities 
were normalized to Renilla luciferase activities and protein concentration. Data points result 
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from three independent experiments, and are presented as mean and standard deviation. P < 
0.05 was considered statistically significant. For the data shown in Suppl. Fig. 10, HEK293 
cells were transfected with ON-TARGETplus SMARTpool siRNA against NUP93, 
NUP153, and NUP188 (GE Dharmacon) at a final concentration of 100 nM using 
lipofectamine® RNAiMAX (Thermo Fisher) following the manufacturer's instructions. 
Experiments were performed 48 hrs after transfection.
Podocyte migration assay
The Podocyte migration assay was performed as previously described.8 Briefly, real-time 
migration assays were performed using the xCELLigence™ system (Roche Applied 
Science) with CIM-plate 16 according to the manufacturer's instructions. Immortalized 
human podocyte with shRNA mediated knockdown of NUP93 (shRNA #1 and shRNA#3) 
were transfected with MOCK-GFP or mouse full-length wildtype Nup93 cDNA 
(Nup93_FL). 36 hrs after transfection, 4 × 104 cells were seeded in serum free medium in 
the upper chambers of the migration plate. The lower chambers were filled with medium 
containing 15% FBS as chemoattractant, or with serum-free medium as control. Changes in 
impedance were analyzed using the RTCA software. Results were plotted as cell index 
(relative podocyte migration) vs. time. Each experiment was performed in triplicates, and 
repeated two times independently. Results are presented as mean with standard deviation.
Podocyte proliferation assay
The proliferation assay was performed using the xCELLigence system™ with E-plates 16 
(Roche Applied Science) according to the manufacturer's instructions. The experiment was 
performed in immortalized human podocytes with shRNA mediated knockdown of NUP93 
(shRNA #1 and shRNA#3). Cells were transfected with MOCK-GFP or mouse full-length 
wildtype Nup93 cDNA (Nup93_FL). 36 hrs after transfection, 2.5 × 104 cells were seeded in 
each well of the E-plate 16. Changes in impedance were analyzed using the RTCA software. 
Results were plotted as cell index (relative podocyte proliferation) vs. time. Each experiment 
was performed in triplicates, and repeated two times independently. Results are presented as 
mean with standard deviation. For the data shown in Suppl. Fig. 6, immortalized human 
podocytes were transfected with ON-TARGETplus SMARTpool siRNA against NUP93, 
NUP153, and NUP188 (GE Dharmacon) at a final concentration of 100 nM using 
lipofectamine® RNAiMAX (Thermo Fisher) following the manufacturer's instructions. 
Experiments were performed 48 hrs after transfection.
In-vitro experiments to assess oxidative stress resistance
To assess oxidative stress resistance in human immortalized podocytes, H2O2 was added to 
cell culture medium at three different doses (100 μM, 250 μM, and 500 μM) that did not 
induce significant apoptosis or changes in cell morphology in control cells. After 60 minutes 
cell were lysed and apoptosis was assessed using an antibody against cleaved caspase-3 (cell 
signaling, #9661) in control (scrambled shRNA) as compared to knockdown cells. The result 
was shown in two independent experiments.
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NUP93 depletion-addback assay in Xenopus laevis eggs
Nuclear assemblies using Xenopus egg extracts immunofluorescence on in vitro assembled 
nuclei, generation of affinity resins, sperm heads and floated unlabeled or DiIC18-labeled 
membranes were carried out as described48 and analyzed on an Olympus FV1000 confocal 
microscope. Nup93 was depleted as in Theerthagiri et al., 2010.31 mRNA encoding human 
Nup93 (GenBank accession NM_014669.4) and the corresponding mutants was prepared 
using the mMESSAGE mMachine kit (Life Technologies) and added to extracts at a 
concentration of 200 ng/μl. The experiment was repeated three times independently, and 100 
nuclei were counted in each experiment. Results are shown as mean and standard deviation.
Knockdown in human podocytes
ShRNA against human NUP93 was subcloned into pSIREN RetroQ for retroviral 
transduction using HEK293T cells. 48 hours after transduction puromycin at a final 
concentration of 4 ug/ml was added to the medium for selection of transduced cells. See 
Suppl. Table 1 for target sequences, and Fig. 3d for knockdown efficiency.
Antibodies
For immunofluorescence experiments the following primary antibodies were used: mouse 
anti-NUP93 (F2), sc-374400, Santa Cruz Biotechnology; mouse anti-SMAD4 (B-8), 
sc-7966, Santa Cruz Biotechnology; and goat anti-Importin7, NB100-1081, Novus 
bioscience; and anti-TRP, mAB414, Covance. Antibodies against Xenopus Nup20531 and 
Nup9349 have been described. Donkey anti-goat Alexa 488 and Alexa-594 conjugated 
secondary antibodies, and DAPI (4′,6-Diamidino-2-Phenylindole, Dihydrochloride) were 
obtained from Invitrogen. For immunoblotting the following primary antibodies were used: 
mouse anti-NUP93 (F2), sc-374400, Santa Cruz Biotechnology; mouse anti-SMAD4 (B-8), 
sc-7966, Santa Cruz Biotechnology; goat anti-Importin7, NB100-1081, Novus bioscience; 
rabbit anti-NUP205, HPA024574, Atlas antibodies, Sigma; rabbit anti-phospho-Smad1/5, 
#9526, cell signaling. HRP labeled secondary antibodies were purchased from Santa Cruz. 
See Supplementary Fig. 12 for characterization of antibodies against human NUP93 and 
NUP205.
Immunofluorescence and confocal microscopy in cell lines
For immunostaining human immortalized podocytes were seeded on coverglasses, and 
grown at permissive temperature. For overexpression studies human podocytes were 
transiently transfected using lipofectamine 2000® following the manufacturer's instructions. 
Experiments were performed 24-48 hrs after transfection. Cells were fixed and 
permeabilized for 10 min using 4% paraformaldehyde and 0.25%Triton-X100. After 
blocking, cells were incubated with primary antibody over-night at 4°C. The cells were 
incubated in secondary antibodies for 90 min at room-temperature, followed by 5 min. 
staining with 1 × DAPI/PBS. Confocal imaging was performed using Leica SP5X system 
with an upright DM6000 microscope and images were processed with the Leica AF software 
suite. Immunofluorescence experiments were repeated at least twice in independent 
experiments.
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Immunofluorescence and confocal microscopy on rat tissues
Frozen tissue sections were permeabilized in 0.25%Triton-X100, blocked in 10% donkey 
serum for an hour at room temperature, and incubated in primary antibody overnight. The 
cells were incubated in secondary antibodies for 90 min at room-temperature, followed by 5 
min. staining with 1 × DAPI/PBS. Confocal imaging was performed using Leica SP5X 
system with an upright DM6000 microscope and images were processed with the Leica AF 
software suite.
Statistical analysis
Results in Fig. 5 are presented as means ± SD for the indicated number of experiments. 
Statistical analysis was performed with a 2-tailed Student t test using GraphPad Prism®. P < 
0.05 was considered statistically significant.
Bioinformatics
Genetic location is according to the February 2009 Human Genome Browser data, hg19 
assembly.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Homozygosity mapping and whole exome sequencing (WES) identify recessive 
mutations of NUP93, NUP205, or XPO5 in 8 families with steroid resistant nephrotic syndrome
(a) Homozygosity mapping identifies seven recessive candidate loci (red circles) in family 
A1671 with steroid resistant nephrotic syndrome (SRNS), and WES identifies a 
homozygous mutation of NUP93 (p.Tyr629Cys). The NUP93 locus (arrowhead) is 
positioned within one of the maximum NPL peaks on chromosome 16q. (b–c) Renal 
histology of A1671-21 shows diffuse mesangial sclerosis (arrowhead) (b) and tubular 
dilation with protein casts (arrow) as well as tubular interstitial infiltration and fibrosis (c). 
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(d) Exon (black-white) and protein domain (red-blue) structure of human NUP93 cDNA. 
Black bar denotes in-frame deletion of exon 13 (192 bp) resulting from a c.1537+1G>A 
mutation in family A1394-21. Three homozygous and three compound-heterozygous 
NUP93 mutations detected in 6 families with SRNS. Arrows indicate positions of mutations 
in relation to exons and protein domains. h, heterozygous; H, homozygous. (e) Conservation 
across evolution of altered amino acid residues for the three NUP93 missense mutations 
(p.Arg388Trp, p.Gly591Val, p.Tyr629Cys). (f) Genetic linkage mapping and WES in family 
A1733 with SRNS identifies a homozygous mutation in NUP205 (p.Phe1995Ser). (g–h) 
Renal histology sections of A1733 showing focal segmental glomerulosclerosis (FSGS). (i) 
Homozygosity mapping and WES in family F1092 with SRNS identifies a homozygous 
mutation in XPO5 (p.Val552Ile). (j) 3D structure of Nic96, the S. cerevisiae ortholog of 
human NUP93 (PDB 2QX5) lacking the coiled-coil domain. Scale bars are: (b,g) 25 μm, (c) 
100 μm, and (h) 50 μm.
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Figure 2. Subcellular localization of NUP93 in podocytes and NUP93 knockdown resulting in 
reduced podocyte migration, proliferation, and impaired resistance to oxidative stress
(a) In BMP7 treated human podocytes the nucleoporin NUP93 (green) and the nuclear 
transport factor importin7 (red) colocalize to a nuclear rim (arrow heads). (b–c) Neonatal rat 
kidney sections were stained with antibodies against NUP93 (green) and importin7 (red). 
Both proteins colocalize in podocyte precursor cells in different stages of glomerular 
development and other structures of the developing kidney. (c) Magnifications of the 
capillary loop and renal vesicle stage. (d) In adult rat glomerulus the nuclear exportin XPO5 
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partially colocalizes with the glomerular slit membrane marker synaptopodin (arrow heads). 
DAPI (blue) stains DNA. Scale bars are 10 μm in a, d and 25 μm in b, c. (e) Knockdown of 
NUP93 in human podocytes using two different shRNAs impairs podocyte migration 
(yellow curve vs. black curve). The decrease in podocyte migration was partially rescued by 
transfection of mouse Nup93 cDNA (blue curve). (f) Upon knockdown of NUP93 using two 
different shRNAs, the proliferation rate of human podocytes is severely impaired (yellow 
curve vs. black curve). Transfection of mouse Nup93 cDNA partially reversed the effect 
(blue curve). Experiments in e, f were performed in triplicates. Data points represent mean 
and standard deviation. (g) Addition of sub-lethal concentrations of H2O2 (100 μM, 250 μM, 
and 500 μM) to human podocyte culture does not induce apoptosis in control cells. In 
contrast, upon knockdown of NUP93 H2O2 induces apoptotic cell death as shown by 
increased cleavage of caspase-3.
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Figure 3. NUP93 mutations interfere with nuclear pore complex (NPC) assembly, and a NUP205 
mutation affects NUP93-NUP205 interaction
(a) Upon overexpression in human podocytes, Myc tagged NUP93 but not the splice site 
mutation del ex13 or the truncating mutation Lys442Asnfs*14, localize to the nuclear 
envelope (arrow heads). Scale bar 10 μm, see also c. (b) Mutations identified in individuals 
with SRNS fail to assemble an intact NPC in a depletion-addback assay in X. laevis egg 
extracts. Upon depletion of NUP93 nuclei fail to assemble properly. Addback of full-length 
or the mutant constructs Gly591Val or Tyr629Cys restore nuclear envelope and NPC 
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assembly. The constructs of the in-frame deletion of exon 13 (del ex13), the missense 
mutation Arg388Trp, and the frameshift mutation Lys442Asnfs*14 lack this ability. Nuclear 
membranes are stained with DiIC18 (red, upper row), DNA with DAPI (blue), NPCs with 
mAB414 (second row, red), and α-Nup93 antibody (third row, green). Scale bar 10 μm, see 
also d. (c) Quantitation of nuclear localization data from (a) resulting from 50 transfected 
cells for each condition. (d) Quantitation of depletion-addback assay data from (b) presented 
as mean and standard deviation resulting from 100 nuclei each from three independent 
experiments. (e) Upon shRNA knockdown of NUP93 (left panel) immortalized human 
podocytes show a reduced expression level of NUP205 (right panel). (f) GFP tagged 
NUP205 precipitates endogenous NUP93 upon overexpression in HEK293 cells. A mutant 
allele of NUP205 identified in SRNS family A1733 (Phe1995Ser) lacks this interaction.
Braun et al. Page 20
Nat Genet. Author manuscript; available in PMC 2016 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. NUP93, importin7, and exportin5 (XPO5) interact with SMAD proteins, and NUP93 
mutations from individuals with SRNS abrogate the interaction with SMAD4 and importin7 
upon coIP in HEK293 cells
(a) C-terminally GFP tagged NUP93 precipitates endogenous SMAD4. (b) C-terminally 
GFP tagged SMAD4 precipitates endogenous NUP93. (c) Upon cooverexpression, GFP 
tagged NUP93 interacts with Myc tagged SMAD4. Mutations (Lys442Asnfs*14, 
Gly591Val, Tyr629Cys) identified in individuals with SRNS abrogate SMAD4 interaction. 
(d) Upon BMP7 stimulation C-terminally GFP-tagged NUP93 interacts with 
phosphorylated/activated SMAD1/5. (e) C-terminally GFP tagged NUP93 precipitates 
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endogenous importin7. (f) C-terminally GFP tagged SMAD4 precipitates endogenous 
importin7. (g) Upon cooverexpression, GFP tagged NUP93 interacts with Myc tagged 
importin7. Mutations (Lys442Asnfs*14, Gly591Val, Tyr629Cys) identified in individuals 
with SRNS abrogate importin7 interaction. (h) GFP tagged SMAD4 precipitates endogenous 
XPO5. Deletion of the SMAD4 nuclear export signal (NES) (aa142-aa149) abrogates the 
interaction with XPO5. Coimmunoprecipitation experiments shown in a, b, d, e, and f were 
confirmed using N-terminally GFP-tagged fusion proteins.
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Figure 5. Knockdown of NUP93 interferes with BMP7-induced activation of SMAD signaling
(a) Stimulation of human podocytes with recombinant BMP7 (rc-BMP7) (100 ng/μl) 
induces nuclear accumulation of SMAD4 in control cells (columns 1 vs. 2). Upon 
knockdown of NUP93 using two different shRNAs (sh1 and sh3) BMP7 fails to induce 
efficient nuclear translocation of SMAD4 (columns 3, 4). Transfection of full-length 
wildtype mouse Nup93 cDNA restores this effect (column 5). White dotted lines mark the 
borders of the nuclear area. Endogenous SMAD4 is stained in red. (b) Transfection of full-
length Nup93 restores BMP7-induced nuclear accumulation of SMAD4 in NUP93 
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knockdown podocytes (column 1). In contrast, cells transfected with clones reflecting all 5 
SRNS mutantions do not show efficient nuclear translocation of SMAD4 (columns 2-6). (c) 
In a luciferase reporter assay, treatment of HEK293 cells with BMP7 increases SMAD 
reporter activity. Knockdown of NUP93 with two different shRNAs (sh1 and sh3) reduces 
SMAD reporter activity in response to BMP7 stimulation. Transfection of mouse full-length 
Nup93 restores a cellular response that is compatible to control cells. In contrast, clones 
reflecting all 5 SRNS mutations fail to rescue the defects in BMP7-SMAD4 signaling. Data 
result from three independent experiments each, and are presented as mean and standard 
deviation. * Indicates statistical significance (p<0.05). (d) Upon stimulation of human 
podocytes with BMP7, endogenous importin7 (green) accumulates in a nuclear rim pattern 
(arrow heads). Knockdown of NUP93 by two shRNAs (sh1 and sh3) inhibits this rim 
formation. Scale bars are 10 μm. Nuclei are stained with DAPI (blue).
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